Literature DB >> 31710398

Is topical alprostadil an usable and reliable alternative to intracavernous injection for penile dynamic duplex ultrasonography?

Davide Arcaniolo1, Giuseppe Bellastella2, Celeste Manfredi1, Marco Terribile1, Dario Ranieri Giordano1, Carmelo Quattrone1, Roberto La Rocca3, Marco De Sio1, Paolo Verze3, Vincenzo Mirone3.   

Abstract

No study has yet been done to evaluate topical alprostadil as a less invasive alternative vasoactive agent for Penile Dynamic Duplex Ultrasonography (PDDU) in the diagnosis of erectile dysfunction. The main aim of our study was to evaluate the usability and reliability of topical alprostadil for PDDU compared with standard intracavernous injection. A further objective was to determine the patients' preference between these two different approaches. During session A, patients received injection while during session B, they received topical alprostadil. Each patient underwent both sessions, 1 week apart from the other. A total of 80 patients were enrolled. After 20 min from drug administration, no significant difference was found between the two procedures in terms of peak systolic velocity and end-diastolic velocity, while Erection Hardness Score was significantly higher with injection. Patients reported less pain/discomfort during the procedure in case of topical alprostadil use and an overall preference towards this examination modality. Topical alprostadil could represent a usable and reliable alternative to intracavernous injection for PDDU, with less discomfort and greater preference by patients.
© 2019 Blackwell Verlag GmbH.

Entities:  

Keywords:  erectile dysfunction; intracavernosal injection; penile dynamic duplex ultrasonography; topical alprostadil

Year:  2019        PMID: 31710398     DOI: 10.1111/and.13480

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  2 in total

Review 1.  News and future perspectives of non-surgical treatments for erectile dysfunction.

Authors:  Celeste Manfredi; Fabio Castiglione; Mikkel Fode; Michal Lew-Starowicz; Javier Romero-Otero; Carlo Bettocchi; Giovanni Corona
Journal:  Int J Impot Res       Date:  2022-07-27       Impact factor: 2.408

2.  Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study.

Authors:  Pablo Garrido-Abad; Isabel Senra-Bravo; Celeste Manfredi; Esaú Fernández-Pascual; Estefanía Linares-Espinós; Manuel Fernández-Arjona; David Varillas-Delgado; Juan Ignacio Martínez-Salamanca
Journal:  Int J Impot Res       Date:  2021-01-22       Impact factor: 2.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.